Daily Hong Kong Stock Market News Briefing (January 23, Thursday)

USHK News
2025.01.23 01:02

Important News

  1. The State Council Information Office held a press conference on vigorously promoting the entry of medium- and long-term funds into the market and promoting the high-quality development of the capital market. Individual Stock News

  2. FOSUN PHARMA (02196.HK): The conditions for the effectiveness of the merger and privatization agreement for its holding subsidiary HENLIUS have not been met, and the merger will not be implemented. HENLIUS will retain its H-share listing status.

  3. China National Offshore Oil Corporation (00883.HK) announced its operational strategy and development plan for 2025, with a daily net production target of over 2 million barrels of oil equivalent/day in 2025, and a full-year dividend payout ratio of no less than 45% from 2025 to 2027.

  4. China Metallurgical Group Corporation (01618.HK) announced that the new contract amount signed by the company in 2024 is RMB 1,248.3 billion, a decrease of 12.4% year-on-year, with the new contract amount in the fourth quarter being RMB 356.61 billion, a decrease of 19.5% year-on-year.

  5. JS Global Life (01691.HK) announced that it expects the group's profit from continuing operations for the fiscal year 2024 to be no less than USD 8.1 million (for the year ending December 31, 2023: USD 70.3 million), a decrease of no more than 88.5% compared to the same period last year.

  6. Shanghai Pharmaceuticals (02607.HK): The company's holding subsidiary Changzhou Pharmaceutical Factory Co., Ltd. has received approval to produce ursodeoxycholic acid capsules.

  7. Harbin Electric (01133.HK): It is expected that the annual net profit attributable to the parent company will be approximately RMB 1.7 billion (approximately RMB 575 million in the same period last year), a significant increase compared to the same period last year.

  8. China Pacific Insurance (02601.HK): It is expected that the net profit attributable to the parent company for 2024 will be approximately RMB 42.2 billion to RMB 46.3 billion, an increase of about 55% to 70% year-on-year.

  9. Luoyang Molybdenum (03993.HK): It is expected that the net profit attributable to the parent company for 2024 will be RMB 12.8 billion to RMB 14.2 billion, an increase of 55.15%-72.12% year-on-year.

  10. Chow Tai Fook (01929.HK): The retail value for the third quarter ending December 31, 2024, decreased by 14.2% year-on-year

Source: USHK News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.